Physix Frontier badgePhysix Frontier
PublishChinese | EN

Aureka Biotechnologies

Apps & Agents
Website ↗
Series B RoundUSD 100M2026-08-11View funding history →
Total funding
USD 200M
Data cutoff
2026-08-16

Company Profile

Aureka Biotechnologies is an AI-native TechBio firm focused on generative antibody drug development. Established in 2023, it combines single-cell screening, yeast-directed evolution, and structural biology. Its AuraIDE platform automates antibody design to reduce costs and improve efficiency in therapeutic discovery.

Founded
2023
Headquarters
Suzhou, China